Julie Bullock - Concepedia

Author

Julie Bullock

Center for Drug Evaluation and Research

Also Known As

J M Bullock, J. Bullock, J.M. Bullock, Julie Bullock, Julie M Bullock, Julie M. Bullock

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Center for Drug Evaluation and Research United States Food and Drug Administration University at Buffalo, State University of New York Roswell Park Comprehensive Cancer Center Novartis (United States)

About

Julie Bullock is an author at Center for Drug Evaluation and Research specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.4K
2	Health Sciences	5	5	676
3	Biostatistics	1	1	23
4	Immunology	1	1	41
5	Marrow Transplantation	1	1	23

Julie Bullock

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review Ping Zhao, L Zhang, Joseph A. Grillo, Clinical Pharmacology & Therapeutics Drug EvaluationTranslational MedicinePhysiologically Based PharmacokineticsPharmacokinetic ModelingPreclinical Drug Evaluation	2010	507
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma Thomas M. Herndon, Albert Deisseroth, Edvardas Kaminskas, Clinical Cancer Research Hematological MalignancyThrombosisTranslational MedicineMultiple Myeloma RefractoryU.s. Food	2013	240
Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate Michael H. Brave, Vicki Goodman, Edvardas Kaminskas, Clinical Cancer Research	2008	239
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski, Clinical Cancer Research Lymphoid NeoplasiaTranslational MedicineHodgkin LymphomaU.s. FoodMedicine	2012	207
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia R. Angelo de Claro, Karen M. McGinn, Nicole Verdun, Clinical Cancer Research Preclinical TherapeuticsTyrosine KinasePathologyFda ApprovalPharmacotherapy	2015	156
The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate Patrick F. Smith, Julie Bullock, Brent M. Booker, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2004	145
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis Albert Deisseroth, Edvardas Kaminskas, Joseph A. Grillo, Clinical Cancer Research Hematological MalignancyAntifibrotic TherapyOncologyU.s. FoodMetronomic Therapy	2012	143
Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT Yanling He, Yibin Wang, Julie Bullock, The Journal of Clinical Pharmacology	2007	97
U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia Firoozeh Alvandi, Virginia E. Kwitkowski, Chia‐Wen Ko, The Oncologist PharmacotherapyPre-clinical PharmacologyMyeloid NeoplasiaHematological MalignancyTranslational Medicine	2013	96
Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice Joseph A. Grillo, Ping Zhao, Julie Bullock, Biopharmaceutics & Drug Disposition	2012	93

Page 1